Investor Presentaiton

14 Commercial execution and innovation Diabetes care Novo NordiskⓇ OzempicⓇ is driving growth in the GLP-1 class, which is still a small proportion of the US diabetes market 32% of diabetes market value is GLP-1 ~8% of diabetes NBRX share prescriptions are GLP-1 80% US GLP-1 NBRx market share ~30% GLP-1 volume market growth Oral GLP-1 0.5% 8% Inj. GLP-1 60% SGLT-2i 8% DPP-4i 7% Insulin 29% 40% OAD 48% 20% 63.1% 45.2% 35.4% 11.9% 6.0% 0% Diabetes volume1 market share by segment Jan 2021 Feb 2022 - OzempicⓇ RybelsusⓇ dulaglutide - NN GLP-1 VictozaⓇ 1 Diabetes volume measured in prescriptions NBRX: New to brand prescription; OAD: oral anti-diabetes meditation Source: IQVIA, left hand side chart is IMS World data from Dec'21 and right hand sight chart is IQVIA data from the week ending 4 February 2022 CMD22 CAPITAL MARKETS DAY

View entire presentation